Dublin, Dec. 14, 2018 (GLOBE NEWSWIRE) -- The "Hepatitis Test Solution/Diagnosis Market by Disease Type (Hepatitis B, HCV, HAV, HDV), Technology (ELISA, RDT, PCR, Transcription Mediated Amplification), End User (Hospitals, Diagnostic Laboratories, Blood Banks, etc.) - Global Forecast to 2023" report has been added to ResearchAndMarkets.com's offering.

The hepatitis test solution/diagnosis market is expected to reach USD 3.37 billion by 2023 from USD 2.66 billion in 2018, growing at a CAGR of 4.9% during the forecast period.

The growth of this market can be attributed to the high burden of hepatitis worldwide, benefits offered by point of care instruments & kits, and initiatives taken by government and non-governmental organizations. However, the lack of a mandate for NAT in developing countries and the high cost of the NAT test are expected to restrain the growth of this market during the forecast period.

By technology, the hepatitis test solution/diagnosis market is segmented into ELISA, rapid diagnostics test, PCR, INAAT, and other technologies. RDT is projected to grow at the highest CAGR during the forecast period. This growth is mainly attributed to the low cost of this test type, its high analytical sensitivity, and its ability to detect all known 11 subtypes of HBsAg.

The market is classified on the basis of disease type into hepatitis B, hepatitis C, and other hepatitis disease. In terms of value, the hepatitis B segment is expected to account for the largest share of the market in 2018. This can primarily be attributed to the rising prevalence of hepatitis B, availability of a large number of hepatitis B diagnostic tests, and the increasing adoption of NAT test in HBV blood screening.

North America is expected to account for the largest share of the global hepatitis test solution/diagnosis market in 2018. This is primarily attributed to factors such as rising adoption of advanced technologies, developed healthcare systems in the US and Canada, and the presence of a large number of leading national clinical laboratories. Followed by North America, Europe is expected to account for the second-largest share of the global hepatitis test solution/diagnosis market in 2018.

Key Topics Covered:

1 Introduction
1.1 Objectives Of The Study
1.2 Market Definition
1.3 Market Scope
1.4 Currency
1.5 Limitations
1.6 Stakeholders

2 Research Methodology
2.1 Primary Data
2.2 Secondary Data
2.3 Key Data From Secondary Sources
2.4 Market Size Estimation
2.5 Market Breakdown And Data Triangulation

3 Executive Summary

4 Premium Insights
4.1 Hepatitis Testing: Market Overview
4.2 Geographic Analysis: Hepatitis Testing Market, By Disease Type (2018)
4.3 Hepatitis Testing Market, By Technology, 2018 Vs. 2023
4.4 Hepatitis Testing Market, By End User, 2016-2023

5 Market Overview
5.1 Introduction
5.1.1 Drivers High Burden Of Hepatitis Increasing Blood Transfusion And Donations Benefits Of Poc Instruments & Kits Awareness Initiatives
5.1.2 Restraints High Cost Of NAT Lack Of Mandate For Nat In Developing Countries
5.1.3 Opportunities Emerging Markets

6 Hepatitis Testing Market, By Disease Type
6.1 Introduction
6.2 Hepatitis B (HBV)
6.3 Hepatitis C (HCV)
6.4 Other Hepatitis Diseases

7 Hepatitis Testing Market, By Technology
7.1 Introduction
7.2 Enzyme-Linked Immunosorbent Assay (ELISA)
7.3 Rapid Diagnostic Tests (RDT)
7.4 Polymerase Chain Reaction (PCR)
7.5 Isothermal Nucleic Acid Amplification Technology (INAAT)
7.6 Other Technologies

8 Hepatitis Testing Market, By End User
8.1 Introduction
8.2 Hospital & Diagnostic Laboratories
8.3 Blood Banks
8.4 Other End Users

9 Hepatitis Testing Market, By Region
9.1 Introduction
9.2 North America
9.2.1 US
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 Rest Of Europe
9.4 Asia Pacific
9.5 Rest Of The World

10 Competitive Landscape
10.1 Market Overview
10.2 Market Ranking Analysis, 2017
10.3 Competitive Situation And Trends
10.3.1 Collaborations, Agreements, And Partnerships
10.3.2 Product Launches And Approvals
10.3.3 Acquisitions

11 Company Profiles
11.1 Abbott Laboratories, Inc.
11.2 Roche Diagnostics
11.3 Bio-Rad Laboratories
11.4 Siemens Healthineers
11.5 Diasorin
11.6 Qiagen
11.7 Danaher Corporation
11.8 Grifols
11.9 Biomrieux SA
11.10 Ortho Clinical Diagnostics (A Part Of The Carlyle Group)
11.11 Fujirebio, Inc. (A Part Of Miraca Group)

For more information about this report visit https://www.researchandmarkets.com/research/dnwj9g/hepatitis_test?w=12

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Infectious Disease Testing